Oncocyte Reports First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q 2024. IVD kits are under development for FDA submission....
Oncocyte to Announce First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the l...
Appian Announces First Quarter 2024 Financial Results First quarter cloud subscription revenue increased 24% year-over-year to $86.6 million MCLEAN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2024. “Appian continues to push technological boundaries in our industry, from AI-backed services to process mining. Organizations globally are recognizing the power and simplicity of the Appian Platform,” said Matt Calkins, CEO & Founder. First Quarter 2024 Financial Highlights: Revenue: Cloud subscription ...
Appian To Announce First Quarter 2024 Financial Results on May 2 MCLEAN, Va., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) today announced that it will release financial results for the first quarter ended March 31, 2024, before the U.S. financial markets open on Thursday, May 2, 2024. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can dial in the same way they alway...
Two Directors at Oncocyte Corporation bought 37,288 shares at 2.950USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Oncocyte Reports Full Year 2023 Financial Results Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP$15.8 million in gross proceeds received from private placement offering$4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectivelyGraftAssure™ transplant product launch on track for...
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purcha...
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the commercialization of ...
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...
Appian to Host Investor Day at Appian World on April 16 MCLEAN, Va., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) announced today that it will host its Investor Day on Tuesday, April 16, 2024 at 1:30 p.m. Eastern Time. The event will take place during Appian World, the company's annual customer conference. A live webcast of the event will be available under the "News and Events " section of the Company's investor relations website at . About AppianAppian is a software company that automates business processes. The Appian AI Platform includes everything you need to design, automate...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.